Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Polyphor AG
  6. News
  7. Summary
    POLN   CH0106213793

POLYPHOR AG

(POLN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Polyphor Hosting Key Opinion Leader Roundtable on Covid-19: The Need for Novel Therapies for Severe Infections and the Potential Role of Balixafortide, a Selective CXCR4 Antagonist

06/08/2021 | 01:33am EDT

EQS Group-Ad-hoc: Polyphor AG / Key word(s): Conference
Polyphor Hosting Key Opinion Leader Roundtable on Covid-19: The Need for Novel Therapies for Severe Infections and the Potential Role of Balixafortide, a Selective CXCR4 Antagonist

08-Jun-2021 / 07:30 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 KR
The issuer is solely responsible for the content of this announcement.


Allschwil, Switzerland, June 8, 2021

Polyphor Hosting Key Opinion Leader Roundtable on Covid-19: The Need for Novel Therapies for Severe Infections and the Potential Role of Balixafortide, a Selective CXCR4 Antagonist

Webinar Roundtable Being Held Thursday, June 10 @ 8amET/2pmCET

Polyphor AG (SIX: POLN) a research driven clinical stage, Swiss biopharmaceutical company committed to discovering and developing best-in-class molecules in oncology and antimicrobial resistance, today announced that it will host a key opinion leader (KOL) roundtable on Covid-19, the need for novel therapies for severe infections and the potential role of balixafortide, a selective CXCR4 antagonist, on Thursday, June 10, 2021 at 8am Eastern Time/2pm Central European Time.

The webinar will feature a presentation by Key Opinion Leaders Thomas Klimkait, Ph.D., University of Basel, Andy Shorr, MD, Georgetown University, and Eliver Ghosn, Ph.D., Emory University, who will discuss the current treatment landscape and unmet medical need in treating patients with COVID-19, and research that demonstrates the importance of the CXCR4 pathway in Covid-associated inflammation and mortality, respectively. Drs. Klimkait, Shorr, and Ghosn will be available to answer questions following the formal presentations.

Polyphor's management team will then discuss novel research findings of balixafortide relevant for COVID-19 infections. Balixafortide is a potent, selective CXCR4 antagonist which is currently also in Phase III development in combination with eribulin in patients with metastatic HER-2 negative breast cancer.

To register for the event, please click here.

Thomas Klimkait, Ph.D. is Research Group Leader for Molecular Virology at the University of Basel. Dr. Klimkait earned his Ph.D. thesis in Biology/Genetics at the Institute of Virology at the University of Cologne and has held various senior positions at the University of Basel, including Laboratory Head Serology, AbtID, Department Biomedicine, and Head of Diagnostic Virology and Serology. Dr. Klimkait is a member of many scientific societies, including the European Society for Translational Antiviral Research (ESAR) and the International AIDS Society, has received numerous awards for his work and co-authored 197 peer-reviewed scientific publications.

Andy Shorr, M.D. is Head, Pulmonary and Critical Care Medicine at Medstar Washington Hospital Center and a Professor of Medicine at Georgetown University. His research focuses on issues related to severe pneumonia, health economics and epidemiology. Dr. Shorr earned his undergraduate degree in Public Policy at Princeton University, his medical degree at the University of Virginia and also holds an MPH from Johns Hopkins University and an MBA from the University of Virginia. Dr Shorr is a fellow of both the American College of Physicians and the American College of Chest Physician. In addition to being a Fullbright Specialist, he has won multiple awards for his bedside teaching and his research.

Eliver Ghosn, Ph.D. is Assistant Professor of Medicine and Pediatrics at Emory University and a faculty member of the Lowance Center for Human Immunology and Emory Vaccine Center. He is also an affiliated faculty member of the Bioinformatics Program at Georgia Institute of Technology. His lab at Emory employs multi-omics single-cell technologies as a systems immunology approach to study the development and function of the immune system at different ages, from fetal life to adulthood. Dr. Ghosn received his Master's degree in Infectious Diseases from the University of São Paulo in Brazil and his Doctorate in Developmental Immunology from the University of São Paulo and Stanford University. He spent 12 years at Stanford University applying high-dimensional technologies to study the development of the immune system, particularly the B-cell and macrophage development, and was Instructor of Genetics there until 2017, when he moved to Emory.

For further information please contact:

For Investors:

Hernan Levett

Chief Financial Officer

Polyphor Ltd.

+41 61 567 16 00

IR@polyphor.com
Mary-Ann Chang

LifeSci Advisors

Tel: +44 7483 284 853

mchang@lifesciadvisors.com
 

For Media:

Bernhard Schmid

LifeSci Advisors

+41 44 447 12 21

bschmid@lifesciadvisors.com

 

About Polyphor

Polyphor is a research driven clinical-stage, Swiss biopharmaceutical company committed to discovering and developing best-in-class molecules in oncology and antimicrobial resistance leveraging the company's leading macrocyclic peptide technology platform. Polyphor is advancing balixafortide (POL6326) in a Phase III trial in combination with eribulin in patients with advanced breast cancer and exploring its potential in other cancer indications. In addition, it has discovered and is developing the Outer Membrane Protein Targeting Antibiotics (OMPTA). OMPTA are potentially the first new class of antibiotics in clinical development in the last 50 years against Gram-negative bacteria. The company's lead OMPTA program is an inhaled formulation of murepavadin for the treatment of Pseudomonas aeruginosa infections in patients with cystic fibrosis. Polyphor is based in Allschwil near Basel and is listed on the SIX Swiss Exchange (SIX: POLN). For more information, please visit www.polyphor.com.

Disclaimer

This press release contains forward-looking statements which are based on current assumptions and forecasts of the Polyphor management. Known and unknown risks, uncertainties, and other factors could lead to material differences between the forward-looking statements made here and the actual development, in particular Polyphor's results, financial situation, and performance. Readers are cautioned not to put undue reliance on forward-looking statements, which speak only of the date of this communication. Polyphor disclaims any intention or obligation to update and revise any forward-looking statements, whether as a result of new information, future events or otherwise.



End of ad hoc announcement
Language: English
Company: Polyphor AG
Hegenheimermattweg 125
4123 Allschwil
Switzerland
Phone: +41 61 567 1600
Fax: +41 61 567 1601
E-mail: info@polyphor.com
Internet: www.polyphor.com
ISIN: CH0106213793
Valor: POLN
Listed: SIX Swiss Exchange
EQS News ID: 1205210

 
End of Announcement EQS Group News Service

1205210  08-Jun-2021 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1205210&application_name=news&site_id=zonebourse_sftp

ę EQS 2021
All news about POLYPHOR AG
09/10POLYPHOR : Wraps Up Sale Of Inhaled Murepavadin To EnBiotix
MT
09/10Polyphor and EnBiotix announce closing of purchase agreement of Inhaled Murepavadin by ..
DJ
09/02GLOBAL MARKETS LIVE : Ford, Walmart, Apple, Volkswagen, Tesla...
09/01POLYPHOR : Signs All-Stock Merger Deal With Rare Disease Company EnBiotix
MT
09/01Polyphor and EnBiotix announce signing of merger agreement and sale of Inhaled Murepava..
DJ
09/01Polyphor AG signed a merger agreement to acquire EnBiotix, Inc.
CI
08/04POLYPHOR : Fails In Late-Stage Trial For Breast Cancer Combo Treatment
MT
08/03EQS-ADHOC : Polyphor provides final update on the Phase III FORTRESS study of balixafortid..
DJ
08/03Polyphor Provides Final Update on the Phase III FORTRESS Study of Balixafortide in Pati..
CI
07/30POLYPHOR : To Layoff 20 Staff After Negative Results From Breast Cancer Treatment Study
MT
More news
Financials
Sales 2021 1,00 M 1,08 M 1,08 M
Net income 2021 -41,4 M -44,8 M -44,8 M
Net Debt 2021 76,8 M 83,1 M 83,1 M
P/E ratio 2021 -0,52x
Yield 2021 -
Capitalization 23,1 M 25,0 M 25,0 M
EV / Sales 2021 99,9x
EV / Sales 2022 5,71x
Nbr of Employees 52
Free-Float 81,5%
Chart POLYPHOR AG
Duration : Period :
Polyphor AG Technical Analysis Chart | POLN | CH0106213793 | MarketScreener
Technical analysis trends POLYPHOR AG
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 1
Last Close Price 1,96 
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
G÷khan Batur Chief Executive Officer
Hernan Levett Chief Financial Officer
Kuno Sommer Chairman
Daniel Obrecht Chief Scientific Officer
Frank T. Weber Chief Medical & Development Officer
Sector and Competitors
1st jan.Capi. (M$)
POLYPHOR AG-75.95%25
CSL LIMITED10.18%103 032
WUXI BIOLOGICS (CAYMAN) INC.14.59%64 160
SAMSUNG BIOLOGICS CO.,LTD.11.62%51 643
BIOGEN INC.19.13%43 475
ALEXION PHARMACEUTICALS, INC.0.00%40 336